PV Watch Daily Blog
Fresh reporting, analysis, and expert insight on drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, and career trends.
CVMP March 2026 Meeting Highlights Keep Veterinary Safety on the Radar
EMA published meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) for 10–12 March 2026. The agency says the meeting was followed by...
EMA’s PMS FAQs Show Where Product Data Friction Still Exists
EMA’s Product Management Service FAQs, updated in January 2026, collect questions raised during PMS events and are intended to complement those sessions. EMA...
Rabies Immunoglobulin Recall Follows Potency Stability Failure
MHRA says Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin 500 IU solution for injection after a stability failure caused...
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Claims
FDA announced on 3 March 2026 that it issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1...
FDA Approves Wegovy HD in 54 Days Under Priority Voucher Pilot
FDA announced on 19 March 2026 that it approved Wegovy HD (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in certain adults. The agency...
What EMA’s 2026 Biologics Safety Page Signals About Ongoing Regulator Transparency
FDA’s 2026 Safety and Availability Communications page for biologics says it was developed to provide the public with important information about the safety...
Global Watch Weekly: MHRA, EMA Shortages and Veterinary Developments
MHRA approved deuruxolitinib for severe alopecia areata in adults and explicitly said it would continue to keep the medicine’s safety and effectiveness under...
Week in PV: FDA B6 Warning, GLP-1 Label Change and PRAC Updates
This week’s major U.S. developments include FDA’s requirement for a vitamin B6 deficiency and seizure warning on carbidopa/levodopa products and the agency’s...
Why Real-Time Safety Visibility Is Becoming a Regulatory Strategy
FDA says AEMS is its new Adverse Event Monitoring System, and the agency also maintains a dedicated page for new safety information or potential signals of...
What the GLP-1 Label Change Says About How Safety Evidence Can De-Escalate
FDA says its comprehensive review of available data did not identify an increased risk of suicidal ideation or behavior with GLP-1 RA medications and...